Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa for anemia in myelodysplastic syndrome
2005-004737-17Phase 2Completed
- Sponsor
- Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli
- Start
- Oct 2005
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darbepoetin alfa in myelodysplastic syndrome (MDS), sponsored by Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli. Primary endpoints: Safety and Anemia response. Started Oct 2005; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2005-004737-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004737-17.